Shire is a global specialty biopharmaceutical company that works closely with specialist physicians to develop and market medicines that enable people living with life-altering conditions to lead better lives.

Replagal (agalsidase alfa) was approved by Health Canada in 2004 and indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. As a result of a change to the drug substance manufacturing process, Replagal was discontinued in Canada in 2014.

Shire is currently conducting a clinical study to evaluate the safety of Replagal in Canadian patients with Fabry disease. While the study is underway, Replagal will not be commercially available in Canada.

For more information on this ongoing study, please click here.